About Pandorum
Pandorum is a company based in Bengaluru (India) founded in 2011 by Tuhin Bhowmick and Arun Chandru. Pandorum has raised $49.92 million across 16 funding rounds from investors including Kotak Mahindra Bank, We Founder Circle and 021 Capital. The company has 27 employees as of December 13, 2024. Pandorum offers products and services including Bioengineered Cornea, Mini Liver, Lung Regeneration, and Technology Platform. Pandorum operates in a competitive market with competitors including Ensoma, Avita Medical, Newcells Biotech, Organogenesis and InSphero, among others.
- Headquarter Bengaluru, India
- Employees 27 as on 13 Dec, 2024
- Founders Tuhin Bhowmick, Arun Chandru
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Pandorum Technologies Private Limited
- Date of Incorporation 16 May, 2011
- Jurisdiction Bengaluru, Karnataka, India
-
Annual Revenue
$84.39 K (USD)301.44as on Mar 31, 2024
-
Net Profit
-$1.51 M (USD)19.88as on Mar 31, 2024
-
EBITDA
-$1.46 M (USD)13.84as on Mar 31, 2024
-
Total Equity Funding
$49.92 M (USD)
in 16 rounds
-
Latest Funding Round
$429.41 K (USD), Series B
Mar 20, 2026
-
Investors
Kotak Mahindra Bank
& 70 more
-
Employee Count
27
as on Dec 13, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Pandorum
Pandorum offers a comprehensive portfolio of products and services, including Bioengineered Cornea, Mini Liver, Lung Regeneration, and Technology Platform.
Treats corneal disorders through regenerative tissue therapy
Supports drug discovery using human liver organoids
Repairs lung damage via exosomal therapy
Enables tissue fabrication for research applications
Funding Insights of Pandorum
Pandorum has successfully raised a total of $49.92M across 16 strategic funding rounds. The most recent funding activity was a Series B round of $429.41 thousand completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Pandorum
Pandorum has secured backing from 71 investors, including angel, venture fund, and institutional investors. Prominent investors backing the company include Kotak Mahindra Bank, We Founder Circle and 021 Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Angel investor network investing in early-stage startups
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Investment in early-stage startups and global community support.
|
Locked | Locked | Locked |
Investor details for Pandorum
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Pandorum
Investment portfolio details for Pandorum
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Pandorum
Detailed financials for Pandorum
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Pandorum Comparisons
Peer comparison for Pandorum
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Pandorum
Pandorum operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ensoma, Avita Medical, Newcells Biotech, Organogenesis and InSphero, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of in vivo stem cell modification technologies and vector-based drug delivery tool
|
|
| Locked | Locked | Locked |
Products for regenerative and respiratory medicine are developed and distributed.
|
|
| Locked | Locked | Locked |
Induced pluripotent stem cell-derived organoid models are developed for research.
|
|
| Locked | Locked | Locked |
Regenerative therapies for wound care are developed and commercialized.
|
|
| Locked | Locked | Locked |
Cell-based assays and 3D microtissues for drug screening are developed.
|
|
| Locked | Locked | Locked |
Developer of stem cells and organoids using proprietary technology
|
Detailed competitors of Pandorum
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Pandorum
Complete news archive for Pandorum
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Pandorum
Pandorum was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Pandorum is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Tuhin Bhowmick is the current CEO of Pandorum. They have also founded this company.
Pandorum is a funded company, having raised a total of $49.92M across 16 funding rounds to date.
As of Dec 13, 2024, the latest employee count at Pandorum is 27.
Annual revenue of Pandorum is $84.39K as on Mar 31, 2024.
Pandorum was founded in 2011 in Bengaluru, India, within the biotechnology sector. Focus is placed on regenerative medicine through 3D printing and fabrication techniques. Products developed include a bioengineered cornea hydrogel for treating blindness, 3D hepatocyte spheroids for drug discovery and liver therapies, and exosome-based cell-free treatments for lung regeneration. Operations center on advancing tissue engineering solutions.
Pandorum's top competitors include Avita Medical, Newcells Biotech and InSphero.
Pandorum offers Bioengineered Cornea, Mini Liver, Lung Regeneration, and Technology Platform.
Pandorum has 71 investors. Key investors include Kotak Mahindra Bank, We Founder Circle, 021 Capital, KITVEN, and BTB Venture.
The valuation of Pandorum is $40.67M as of Aug 2023.